P16 Hypermethylation and KRAS Mutation Are Independent Predictors of Cetuximab Plus FOLFIRI Chemotherapy in Patients With Metastatic Colorectal Cancer

Cancer Research and Treatment - South Korea
doi 10.4143/crt.2014.314
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Korean Cancer Association

Related search

Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer

JAMA Oncology
Cancer ResearchOncology
2019English

FOLFIRI Plus Panitumumab in the Treatment of Wild-Type KRAS and Wild-Type NRAS Metastatic Colorectal Cancer

World Journal of Surgical Oncology
SurgeryOncology
2018English

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer
Cancer ResearchOncology
2017English

Predictive Value of TLR7 Polymorphism for Cetuximab-Based Chemotherapy in Patients With Metastatic Colorectal Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

KRAS Mutation Analysis of Single Circulating Tumor Cells From Patients With Metastatic Colorectal Cancer

BMC Cancer
Cancer ResearchOncologyGenetics
2017English

A Phase 2 Randomised Study of Veliparib Plus FOLFIRI±bevacizumab Versus Placebo Plus FOLFIRI±bevacizumab in Metastatic Colorectal Cancer

British Journal of Cancer
Cancer ResearchOncology
2018English

Phase I Trial of Oxaliplatin Plus S-1 Chemotherapy in Patients With Metastatic Colorectal Cancer

Oncology Letters
Cancer ResearchOncology
2010English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy